Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological evaluation. The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment plans for the treatment and management of the BH4 deficiency need to be developed individually, usually including pharmacotherapy, rehabilitation interventions, regular follow-up, and multidimensional management.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic disorders have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions, with timely adjustment according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the deficiency in the malignant BH4 of urethritis.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.